Development of Neurotensin-based Analgesics

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43GM079044-01
Agency Tracking Number: GM079044
Amount: $163,945.00
Phase: Phase I
Program: SBIR
Awards Year: 2006
Solicitation Year: 2006
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Small Business Information
ARGOLYN BIOSCIENCE, INC.
ARGOLYN BIOSCIENCE, INC., 2750 Speissegger Drive, Suite 110, NORTH CHARLESTON, SC, 29405
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 THOMAS DIX
 (843) 266-0851
 tad@argolyn.com
Business Contact
 PEARCE GILBERT
Phone: (843) 266-0851
Email: MPG@ARGOLYN.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Chronic, neuropathic pain is one of the most important unmet medical needs in the United States, affecting tens to hundreds of millions of people nationwide at some time during their lives. Novel therapeutic approaches are desperately needed. The brain peptides neurotensin (NT) and its fully active derivative NT[8- 13] have been shown to exhibit considerable, long-term analgesic activity, however the compounds are unable to be delivered across the blood brain barrier. In previous efforts, we have engineered a compound, ABS201, that possesses significant antipsychotic potential when orally administered; recently, we have demonstrated using an appropriate rat model of neuropathic pain that it also has dramatic analgesic activity. These activities are mediated through the compound?s activity as an agonist of neurotensin receptor- (NTR-) 1 and NTR-2, respectively. While ABS201 has considerable promise for development as an analgesic, we hypothesize that further rational design will enable identification of a derivative in which NTR-2/NTR-1 receptor selectivity can be increased such that the antipsychotic activity is minimized or eliminated. Three Specific Aims will be completed to address the hypothesis. In Specific Aim 1, a set of 10 derivatives of ABS 201 will be synthesized that are designed to improve selectivity of the compound for NTR-2 over NTR-1 and thus retaining analgesic activity. These compounds (as well as ABS201) will be evaluated in Specific Aim 2 for analgesic activity in three rat models, the tail flick, hotplate and formalin assays for chronic pain. Both IP and oral dosing will be performed for all compounds. In Specific Aim 3, other potential discriminators, including NTR-2 and NTR-1 binding, serum stability and functional agonism will be evaluated. From the results of these studies, a lead will be identified for advancement into Phase 2 of this project, which will include further evaluation of the compound?s efficacy, potential for toxicity and pharmacokinetic characterization appropriate for submission of an IND. Specific Aim 1 will be completed at Argolyn Bioscience while Specific Aims 2 and 3 will be completed under a subcontract at the Medical University of South Carolina. Chronic, neuropathic pain is one of the most important unmet medical needs. An orally active derivative of the brain peptide neurotensin has been identified that exhibits potent analgesic activity in rats equivalent to morphine but with a unique mechanism of activity. This compound has the potential for development as a novel therapeutic agent for chronic pain.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government